
GLP-1 agonists – too good to be true?
By Juliette Martin, Nutritional Therapist: Over the past year, a family of medications called GLP-1 agonists, often referred to as the ‘skinny jab’ has captured widespread media attention.
Providing independent clinical excellence since 2005
Posted on Thursday August 15, 2024 in Health Screening
While predicting a heart attack with absolute certainty may still be beyond our reach, the ability to identify patients at high risk is a significant step forward. The latest techniques used to find people at risk are summarised in a related article.
Once a person’s risk of future heart attack has been assessed as ‘high risk’, several strategies can be employed to reduce that risk.
The first step is to investigate all modifiable underlying causes. Increasingly this requires a mixture of blood tests and continuous glucose monitoring- which we offer as part of our metabolic health assessment.
Once we have the assessment in place most cardiologists would recommend following a prevention plan that includes:
By identifying individuals at high risk and providing them with personalised treatment plans, a proactive approach can significantly reduce the incidence of heart attacks and improve outcomes for millions of people. While we may never be able to predict a heart attack with the same certainty as we predict the weather, the ability to assess and mitigate risk is a powerful tool in the fight against heart disease.